Proposal to widen access to levonorgestrel intrauterine system in DHB hospitals
This proposal would result in the restrictions on use of levonorgestrel IUS being widened to include endometriosis, as well as amending the restriction relating to use in heavy menstrual bleeding in hospital only. Closes: Thursday, 24 October 2013.
Proposal relating to the listing of ethinyloestradiol 20 mcg with levonorgestrel 100 mcg and ethinyloestradiol 30 mcg with levonorgestrel 150 mcg tablets
PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Actavis New Zealand Ltd for the oral contraceptives ethinyloestradiol 20 mcg with levonorgestrel 100 mcg and ethinyloestradiol 30 mcg with levonorgestrel 150 mcg. Closed: Tuesday, 22 October 2013.
Proposal to amend the Practitioner’s Supply Order rules relating to certain antibiotics for rheumatic fever prevention
PHARMAC is seeking feedback on a proposal to amend the Pharmaceutical Schedule General Rules regarding a Practitioner’s Supply Order (PSO) in relation to the provision of certain antibiotics for the national Rheumatic Fever Prevention Programme (RFPP). Closes: 22 October 2013.
RFP - Supply of somatropin
PHARMAC invites proposals for the supply of somatropin in New Zealand. Closed.
RFP - Radiological contrast media
PHARMAC invites proposals for the supply of Radiological Contrast Media in New Zealand. Closed.
September 2013 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2011/12 Invitation to Tender, dated 1 November 2011 and the 2012/13 Invitation to Tender, dated 31 October 2012.
Proposal relating to the listing of haemophilia treatments
PHARMAC is seeking feedback on a proposal to fund a number of haemophilia treatments. Closed: Thursday, 10 October 2013.
Easier access to funded enzyme replacement therapy
PHARMAC is providing greater funded access to the expensive enzyme replacement therapy imiglucerase (Cerezyme), mainly expanding its use in children.
Proposal to widen hospital funding restrictions for rituximab
PHARMAC seeks feedback on a proposal to fund rituximab for more indications in hospitals. Closed: Monday, 30 September 2013.
Approval of proposal to fund riluzole for amyotrophic lateral sclerosis (motor neurone disease)
PHARMAC is pleased to announce the approval of an agreement to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease) from 1 October 2013, subject to some restrictions.
August tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.
ROI - Wound care products
PHARMAC invites Registrations of Interest (ROIs) for listing agreements for the supply of Wound Care Products via listing on the Pharmaceutical Schedule to District Health Board hospitals from parties who are able to supply or procure the supply of the Wound Care Products. Closed.
Four students receive pharmacy scholarships
An outstanding calibre of applications has seen the Hiwinui Heke pharmacy scholarships shared among four Māori pharmacy students this year.
Proposals for influenza vaccine
PHARMAC is seeking feedback on a proposal to list two brands of influenza vaccine in the Pharmaceutical Schedule for the 2014, 2015, and 2016 influenza seasons. Closed: 4 pm, Tuesday, 3 September 2013.
Approval of proposal to amend the definition of Specialist within the Pharmaceutical Schedule
PHARMAC is pleased to announce the approval of a proposal to amend the definition of the term Specialist within the Pharmaceutical Schedule.
Listing of alternate brands of enalapril maleate tablets
Due to a pharmacy level recall of m-Enalapril tablets certain alternative products will be listed fully subsidised in the Pharmaceutical Schedule from 12 August 2013.
Approval of proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease
PHARMAC is pleased to announce the approval of a proposal to widen access to imiglucerase (Cerezyme) from 1 September 2013.
Approval of decisions involving boceprevir and pegylated interferon with/without ribavirin
PHARMAC is pleased to announce the approval of an agreement for the listing of boceprevir (Victrelis), and to amend the listing of pegylated interferon with/without ribavirin (Pegasys and Pegasys RBV Combination Pack).
Approval of proposal to remove the Special Authority from Arrow-Venlafaxine XR
PHARMAC is pleased to announce the approval of an agreement to remove the Special Authority and hospital restrictions from the Arrow-Venlafaxine XR brand of venlafaxine from 1 September 2013, in conjunction with a price decrease.
Proposal to list riluzole for the treatment of amyotrophic lateral sclerosis (motor neurone disease)
PHARMAC seeks feedback on a provisional agreement to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease). Closed: 5pm, Thursday, 22 August 2013.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Media queries
Media phone is monitored 9am–5pm weekdays
